Join the Spinal Muscular Atrophy group to help and get support from people like you.
Spinal Muscular Atrophy News
FDA Approves Tablet Form of Evrysdi for Spinal Muscular Atrophy
TUESDAY, Feb. 18, 2025 – The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA). ...
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
South San Francisco, CA – February 12, 2025 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a ...
Spinal Zap Implant Helps Muscle Disease Patients Regain Strength
WEDNESDAY, Feb. 5, 2025 – A new spinal cord implant may help people with spinal muscular atrophy (SMA) regain some muscle function, giving them stronger movement and improved walking ability,...
Link Between T2DM, Spinal Degenerative Disorder May Be Method-Dependent
TUESDAY, July 23, 2024 – The association between type 2 diabetes mellitus (T2DM) and spinal degenerative disorders (SDDs) may be method-dependent, according to a study published online July 3 in The...
Spinal Cord 'Wraparound' Device Could Help Treat Paralysis
THURSDAY, May 9, 2024 – A tiny, flexible device that wraps around the spinal cord could be a breakthrough in the treatment of spinal injuries. The device, developed by a University of Cambridge...
FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old
SOUTH PLAINFIELD, N.J., May 31, 2022 /PRNewswire/ – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi...
FDA Approves Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older
South San Francisco, CA – August 7, 2020 – Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi (risdiplam) for treatment of...
FDA Approves Zolgensma (onasemnogene abeparvovec-xioi) Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy
May 24, 2019 – The U.S. Food and Drug Administration today approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with...
FDA Approves Spinraza (nusinersen) for Spinal Muscular Atrophy
December 23, 2016 – The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and...